All manuscripts
Publications CAR T Cells G-Rex®24 Well Plate

Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice

Published Journal Cytotherapy

Share
9 pages Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice — Cytotherapy, 2025

Overview

This paper describes the engineering of allogeneic CD19 CAR T cells with FKBP12 knockout to resist mTOR inhibitors like tacrolimus and rapamycin. The study utilized 24-well G-Rex® plates for the recovery and expansion of nucleofected T cells. These cells demonstrated deep B-cell depletion in immunosuppressed mice.

What this paper found

Allogeneic CD19 CAR T cells that combine hypoimmune editing (HLA class I and II depletion with CD47 overexpression) with FKBP12 knockout stayed active in the presence of tacrolimus and rapamycin and controlled Nalm6 leukemia in immunosuppressed humanized mice. In vitro, FKBP12-knockout cells killed B cells and Nalm6 cells at high drug concentrations, while unedited CAR T cells failed. Hypoimmune cells also avoided allogeneic T-cell, NK-cell and macrophage responses. Mice received 350,000 CAR T cells three days after 50,000 Nalm6 cells. Over 25 days, only hypoimmune FKBP12-knockout cells prevented tumor expansion in all 5 mice, engrafted in spleen and bone marrow, and depleted bone marrow CD19+ cells.

Note: Preclinical study in humanized mice with small groups of 3 to 5 animals; the authors state that animals within the same group showed consistent outcomes and that clinical assessment should come next.

In stark contrast, HIP-FKBPKO CAR T cells reliably prevented Nalm6 expansion in all 5 mice of that group (Figure 5G). — Xiaomeng Hu, Andrew McAlister, Jeremy Kinder, Adam Johnson, Kathy White, Carolin B. Caruso, Chenyan Wang, Ron Basco, Corie Gattis, Annabelle Friera, Tobias Deuse, Sonja Schrepfer, Cytotherapy

Study details

Authors
Xiaomeng Hu, Andrew McAlister, Jeremy Kinder, Adam Johnson, Kathy White, Carolin B. Caruso, Chenyan Wang, Ron Basco, Corie Gattis, Annabelle Friera, Tobias Deuse, Sonja Schrepfer
Institution
Sana Biotechnology Inc., South San Francisco, CA, USA · Department of Surgery, Division of Cardiothoracic Surgery, Transplant and Stem Cell Immunobiology (TSI)-Lab, University of California San Francisco, San Francisco, California, USA
Journal
Cytotherapy
Year
2025
PMID / PMC
PMID: 40650653
G-Rex® model(s)
G-Rex®24 Well Plate
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

After CRISPR/Cas9 nucleofection of lentivirally transduced CD4+ and CD8+ T cells, the edited cells were recovered and transferred to 24-well G-Rex® plates. Cells were split and IL-2 was replenished every 48 hours, with cryopreservation on day 8 post-activation.

Explore related

Full citation

Hu X, McAlister A, Kinder J, et al. Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice. Cytotherapy. 2025;27(10):1190-1198.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →